Hofseth BioCare ASA: Key OmeGo(TM) patent notice of allowance in the US and new study on ProGo(TM)
August 02 2016 - 2:45AM
Hofseth BioCare ASA («HBC»)
is pleased to announce that the US patent office has issued a
Notice of Allowance on one of HBC's key licensed-in salmon oil
patent applications - "Method of lowering circulating oxidized low
density lipoprotein-beta-2-glycoprotein 1 complex for treatment of
atherosclerosis".
The grant of this patent
will allow HBC to bolster its marketing for improved heart health
with a unique and proprietary mechanism of action now with patent
protection in the largest nutraceutical market in the world.
HBC has also just completed
a new study to evaluate the efficacy of Endurance tablets of
ProGo(TM) to increase vitality, energy and general wellbeing in
normal patients. The study was done with 4 grams per day of
ProGo(TM) Endurance tablets for 4 weeks.
The study showed a
significant increase in energy, vitality and improvement in general
wellbeing after the 4 week trial. This trial shows that even small
doses of ProGo(TM) will stimulate energy and vitality in normal
individuals.
For more information, please
contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mobile: +47 936 32 966
Email: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech company that offers high-value
ingredients and
finished products for humans and pets. The company is founded on
the core values of sustainability, traceability and optimal
utilization of natural resources. Through an innovative hydrolysis
technology, HBC is able to preserve the quality of salmon oil,
proteins and calcium, prepared of fresh salmon off-cuts. HBC's
objective is to contribute to the efficient use of marine resources
and deliver quality products for ingredients and finished consumer
products in the nutrition market.
This information is subject
of the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire
HUG#2032444